Percentage of Participants With Depressive Recurrence After Time (t) in Days Every Visit from Week 34 up to Week 86 (Maintenance Phase) [clinicaltrials_resource:0461c103f9ae88c77aa070e009db6ea0]
duloxetine 60-120 mg every day (QD), by mouth (PO) for 34 weeks followed by duloxetine 60-120 mg QD, PO for up to 54 weeks
clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]
Percentage of Participants With Depressive Recurrence After Time (t) in Days Every Visit from Week 34 up to Week 86 (Maintenance Phase) [clinicaltrials_resource:0461c103f9ae88c77aa070e009db6ea0]
duloxetine 60-120 mg every day (QD), by mouth (PO) for 34 weeks followed by duloxetine 60-120 mg QD, PO for up to 54 weeks
Bio2RDF identifier
0461c103f9ae88c77aa070e009db6ea0
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:0461c103f9ae88c77aa070e009db6ea0
measure [clinicaltrials_vocabulary:measure]
Percentage of Participants With Depressive Recurrence After Time (t) in Days
time frame [clinicaltrials_vocabulary:time-frame]
Every Visit from Week 34 up to Week 86 (Maintenance Phase)
description
duloxetine 60-120 mg every day ...... 0 mg QD, PO for up to 54 weeks
identifier
clinicaltrials_resource:0461c103f9ae88c77aa070e009db6ea0
title
Percentage of Participants Wit ...... to Week 86 (Maintenance Phase)
@en
type
label
Percentage of Participants Wit ...... 1c103f9ae88c77aa070e009db6ea0]
@en